Guanylin and Uroguanylin: Intestinal Peptide Hormones Activating Guanylate Cyclase-C with cGMP/CFTR-Mediated Chloride Secretion and the Basis for Linaclotide and Plecanatide Therapy in Research

# Guanylin and Uroguanylin: Intestinal Peptide Hormones Activating Guanylate Cyclase-C with cGMP/CFTR-Mediated Chloride Secretion and the Basis for Linaclotide and Plecanatide Therapy in Research

Introduction

The regulation of intestinal fluid and electrolyte transport is fundamental to both normal bowel function and the pathophysiology of diarrheal diseases and constipation. For decades, the intestinal guanylate cyclase receptor GCC (guanylate cyclase-C, also known as GUCY2C) was known as the target of bacterial heat-stable enterotoxins (STa) — the mechanism by which enterotoxigenic Escherichia coli (ETEC) causes traveler's diarrhea. The discovery of guanylin (1992) and uroguanylin (1993) as endogenous mammalian peptides that activate the same receptor transformed our understanding: GCC is not a foreign target hijacked by bacteria, but an endogenous regulatory receptor with physiological ligands.

Guanylin and uroguanylin, encoded by GUCA2A and GUCA2B respectively, are small cysteine-rich peptides produced by intestinal enterochromaffin cells and goblet cells. They bind GCC on the apical surface of intestinal epithelial cells → activate particulate guanylate cyclase → elevate intracellular cGMP → activate protein kinase G II (PKGII) and cGMP-dependent pathways → phosphorylate CFTR (cystic fibrosis transmembrane conductance regulator) → chloride and bicarbonate secretion into the lumen → fluid secretion → increased intestinal motility.

The clinical payoff from this biology was substantial: linaclotide (Linzess) and plecanatide (Trulance), both synthetic GCC agonists, received FDA approval for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) — providing new therapeutic options for conditions affecting hundreds of millions globally. These drugs also demonstrated an unexpected visceral analgesic effect (reducing abdominal pain independent of laxation) through cGMP/PKG-mediated suppression of nociceptive signaling, revealing a novel gut-brain axis mechanism.

Discovery

The STa Connection

The story begins with E. coli heat-stable enterotoxin (STa), a small cysteine-rich peptide produced by ETEC strains that causes profuse watery diarrhea. STa was known to activate intestinal particulate guanylate cyclase as early as the 1980s, but the receptor (GCC) was not cloned until 1992.

Currie et al. (1992) discovered guanylin while searching for an endogenous intestinal peptide that activates the STa receptor. They identified a small peptide in rat small intestinal mucosa that reproduced the guanylate cyclase-activating activity of STa, naming it guanylin (PNAS,).

Hamra et al. (1993) subsequently identified uroguanylin from urine (hence the name) — a related peptide with distinct activity and different distribution (PNAS,).

GCC/GUCY2C (guanylate cyclase-C) was independently characterized as the cell-surface receptor activated by both endogenous guanylin/uroguanylin and exogenous bacterial STa.

Gene Structure and Peptide Biochemistry

Guanylin (GUCA2A)

Gene: GUCA2A (chromosome 1p34-p33), 3 exons

Precursor: preproguanylin (115 aa) → proguanylin (94 aa) → active guanylin (15 aa)

Active guanylin structure:

• •15 amino acids (PGTCEICAYAACTGC)
• •Two disulfide bonds: Cys7-Cys15 and Cys4-Cys12 (using the active peptide numbering)
• •These disulfide bonds create a "cysteine knot-like" bicyclic structure critical for GCC binding
• •No post-translational glycosylation
• •Molecular weight: ~1.5 kDa

Molecular forms:

Guanylin exists as two conformers (A and B) in equilibrium — determined by the cis/trans configuration of the Pro-Gly peptide bond at the N-terminus. The A conformer (trans) is more active; B conformer (cis) less active. The conformer ratio is pH-dependent: at low pH (intestinal lumen after a meal), the A conformer predominates.

Uroguanylin (GUCA2B)

Gene: GUCA2B (chromosome 1p34-p33), located adjacent to GUCA2A — tandem gene duplication

Precursor: preprouroguanylin (112 aa) → prouroguanylin (86 aa) → active uroguanylin (16 aa)

Active uroguanylin structure:

• •16 amino acids (NDDCELCVNVACTGCL)
• •Same bicyclic disulfide pattern as guanylin
• •Key difference: no conformer equilibrium — uroguanylin does not have the Pro-Gly motif
• •More stable in alkaline conditions (small intestinal pH) — may explain why uroguanylin is particularly active in the small intestine while guanylin dominates in the colon (lower pH)

Comparison with Bacterial STa

Bacterial STa (STp/STh) is a 18-19 aa peptide with the same bicyclic disulfide structure as guanylin/uroguanylin, with nearly identical residues at the GCC-binding core. The three peptides share a common pharmacophore: the Cys-Glu-Cys-Cys core (positions 7-10 in the alignment). STa is essentially a molecular mimic of uroguanylin with much higher GCC affinity (Kd ~30 pM vs. uroguanylin Kd ~20 nM).

GCC (GUCY2C): The Receptor

GUCY2C gene (chromosome 12p12.3) encodes guanylate cyclase-C:

• •Extracellular domain (~430 aa): ligand-binding; contacts the Cys-Glu-Cys-Cys pharmacophore of guanylin/uroguanylin/STa
• •Single transmembrane helix
• •Intracellular kinase homology domain (KHD, ~250 aa): structural but no kinase activity; regulatory; dimerization
• •C-terminal guanylate cyclase catalytic domain (~250 aa): produces cGMP from GTP; requires Mn²⁺; activated by ligand binding

Expression:

• •Intestinal epithelium (primary site): highest expression on villous enterocytes and colonocytes; apical membrane orientation restricts luminal access
• •Renal tubules: low expression; may contribute to renal sodium regulation
• •Liver: low expression
• •Brain: limited neurons (including dorsal root ganglia — relevant to visceral pain)
• •Lung: some epithelial expression

GCC is remarkably intestine-restricted — making it an excellent therapeutic target (low systemic off-target effects).

Activation Mechanism

Guanylin/uroguanylin/STa → bind GCC extracellular domain → allosteric conformational change in KHD → disinhibition/activation of cyclase domain → GTP → cGMP.

Key mechanistic features:

• •pH dependence: GCC activity is potentiated at acidic pH (simulating post-meal intestinal conditions) when guanylin A-conformer predominates — a functional link between meal-induced acidification and intestinal fluid regulation
• •Receptor desensitization: chronic STa exposure → GCC downregulation; acute ligand exposure → receptor internalization (important for traveler's diarrhea tolerance)

Downstream Signaling: cGMP → CFTR → Fluid Secretion

cGMP Production and PKG II

After GCC activation:

1. cGMP rises rapidly (within minutes) in enterocytes

2. cGMP activates PKGII (cGMP-dependent protein kinase II, membrane-anchored) — the primary effector in intestinal epithelium

3. PKGII phosphorylates multiple targets:

CFTR Phosphorylation and Activation

CFTR (SLC7A11/ABCC7) is the ATP-dependent chloride channel defective in cystic fibrosis. In normal intestinal epithelium:

1. PKGII phosphorylates CFTR R-domain (regulatory domain)

2. CFTR opens → chloride (Cl⁻) secretion into intestinal lumen

3. Additionally, PKGII activates the SLC26A3 Cl⁻/HCO₃⁻ exchanger → bicarbonate (HCO₃⁻) secretion

4. NHE3 (Na⁺/H⁺ exchanger 3) is inhibited by PKGII → reduced Na⁺ absorption

5. Net effect: luminal Cl⁻, HCO₃⁻, and H₂O accumulation → softened stool, increased transit

GCC-Mediated Visceral Analgesia: The Unexpected Discovery

During linaclotide clinical development, patients reported significant reductions in abdominal pain — disproportionate to any laxative effect and occurring at doses below those maximally stimulating secretion. This unexpected visceral analgesic effect was investigated mechanistically:

1. Subepithelial cGMP signaling: cGMP produced by GCC on enterocytes leaks through gap junctions or paracrine diffusion to reach subepithelial nociceptive afferent nerve fibers (colonic high-threshold mechanoreceptors, CTMRs)

2. cGMP activates PKGII on dorsal root ganglia (DRG) neurons expressing GCC

3. Inhibition of voltage-gated Na⁺ channels (Nav1.7, Nav1.8): PKGII phosphorylates and reduces current through Nav channels → reduced firing threshold of nociceptors

4. Net effect: reduced visceral hypersensitivity, characteristic of IBS

This GCC-cGMP-PKG-Nav axis represents a novel gut-brain pain modulation mechanism — a major conceptual advance in IBS pathophysiology.

Physiological Regulation of Guanylin/Uroguanylin

Production site: Enterochromaffin cells (ECs), goblet cells, colonocytes in the intestinal epithelium; also produced in kidneys.

Meal-driven secretion: Guanylin and uroguanylin are released post-prandially — particularly uroguanylin, which is proposed to function as an "intestinal natriuretic hormone" coupling dietary sodium/fluid intake to intestinal fluid and renal sodium handling.

Prouroguanylin in circulation: The predominant circulating form is prouroguanylin (the propeptide), not active uroguanylin. Conversion to active uroguanylin occurs locally at the intestinal epithelium by an as-yet-incompletely-characterized protease. This creates an oral-endocrine hormone axis distinct from classical systemic hormones.

GCC downregulation in colorectal cancer: GCC expression is lost as colorectal cancer progresses (dedifferentiation marker). This observation led to the hypothesis that loss of guanylin → reduced GCC signaling → reduced cGMP → increased proliferation and survival in colonocytes = tumor-suppressive role for the guanylin/GCC axis.

Therapeutic GCC Agonists: Linaclotide and Plecanatide

Linaclotide (Linzess)

Developed by Ironwood Pharmaceuticals and AstraZeneca, linaclotide is a 14-amino acid synthetic GCC agonist inspired by bacterial STa but with a modified structure for stability and tolerability.

Structure: CCEYCCNPACTGCY — contains three disulfide bonds (vs. guanylin's two); the additional disulfide increases stability. MW ~1.53 kDa.

Mechanism:

• •GCC agonist with Kd ~100-500 pM (much higher affinity than guanylin or uroguanylin)
• •Stimulates cGMP → PKGII → CFTR chloride secretion → intestinal fluid secretion
• •Also reduces visceral pain via cGMP/PKG/Nav mechanism
• •Minimal systemic absorption (<1% bioavailability) — acts locally in intestinal lumen

FDA Approvals:

• •August 2012: Irritable bowel syndrome with constipation (IBS-C) in adults
• •August 2012: Chronic idiopathic constipation (CIC) in adults
• •2017: Chronic idiopathic constipation in pediatric patients (8-17 years) — based on safety data; efficacy in adults extrapolated

Key clinical trials:

• •IBSOS and LIN-MD-31 Phase III trials: linaclotide 290 µg QD significantly improved stool frequency, consistency, straining, abdominal pain, and overall IBS-C symptom relief vs. placebo
• •Black box warning added 2012: contraindicated in pediatric patients under 6 years due to mouse lethality data (dehydration at high doses); pediatric patients 6-17 use with caution

Plecanatide (Trulance)

Developed by Synergy Pharmaceuticals (now Bausch Health), plecanatide is a 16-amino acid GCC agonist designed to closely mimic the structure and pH-dependent activity of uroguanylin.

Structure: closely mirrors uroguanylin with amino acid substitutions for stability; same dual disulfide pattern. MW ~1.68 kDa.

Key difference from linaclotide: Plecanatide retains pH-dependent GCC activation — it is more active at slightly acidic pH (simulating proximal small intestinal conditions post-meal), potentially providing more "physiological" on-demand activation. In contrast, linaclotide is active at neutral pH.

FDA Approvals:

• •January 2017: Chronic idiopathic constipation (CIC) in adults
• •April 2018: Irritable bowel syndrome with constipation (IBS-C) in adults

Dose: 3 mg once daily.

Comparison Table: Linaclotide vs. Plecanatide vs. Guanylin vs. Uroguanylin

GCC in Colorectal Cancer: Tumor Suppression and Theranostics

Tumor Suppressor Function

GUCY2C expression is lost early in colorectal cancer progression: this downregulation correlates with tumor dedifferentiation, reduced cGMP, loss of cGMP-dependent anti-proliferative signaling, and increased proliferation.

Restoring GCC signaling (with uroguanylin/linaclotide or GCC-targeted approaches) in GCC-expressing tumors reduces proliferation, increases apoptosis, and suppresses invasion in preclinical models. The guanylin/GCC axis is thus a candidate tumor suppressor mechanism in colorectal carcinogenesis.

GCC as an Immunotherapy Target

Indium-111 or Lutetium-177 labeled STa analogs targeting GCC on colorectal cancer cells have been explored for radioimmunotherapy — GCC's luminal surface expression makes it accessible to luminal agents.

Labetuzumab govitecan (anti-CEACAM5-SN-38 ADC) for colorectal cancer inadvertently validated the concept of GCC-positive tumor targeting; direct GCC-targeting antibody-drug conjugates are in preclinical development.

Research Tools and Models

Current Research Frontiers

Prouroguanylin as a Post-Prandial Satiety Hormone

Plasma prouroguanylin rises post-prandially and acts centrally — prouroguanylin may be an "intestinal hormone" signaling satiety to the hypothalamus via the vagus nerve. Obese individuals have reduced circulating prouroguanylin, suggesting impaired "intestinal GCC satiety signaling" in obesity.

GCC and Intestinal Stem Cell Biology

GCC activation by cGMP suppresses Wnt/β-catenin signaling in intestinal crypts — the primary proliferative drive for intestinal stem cells. Loss of guanylin/GCC in colorectal cancer may remove a cGMP-Wnt antagonism that normally restrains proliferation.

Oral Uroguanylin Replacement for CIC

Recombinant oral uroguanylin has been proposed as a "physiological replacement" approach for CIC — in contrast to synthetic analogs like linaclotide. Clinical development of oral uroguanylin-based therapy is ongoing.

GCC-Targeted Drug Delivery

GCC's luminal expression, intestinal restriction, and retention in some GI cancers make it an attractive drug delivery receptor. Oral GCC-targeted nanoparticles carrying cytotoxic payload to GCC-positive GI tumors are in preclinical development.

Guanylin/Uroguanylin in Renal Physiology

Uroguanylin is produced by renal tubular cells and may regulate sodium reabsorption in the distal nephron through GCC-cGMP on collecting duct cells. An intestine-kidney axis where dietary sodium intake → intestinal uroguanylin release → renal GCC → natriuresis is proposed as a novel mechanism of blood pressure regulation independent of the RAAS.

Conclusion

Guanylin and uroguanylin represent an elegant example of how understanding the molecular target of a bacterial pathogen (STa/GCC) ultimately led to the identification of a novel endogenous hormone system and, subsequently, FDA-approved therapies for common gastrointestinal conditions affecting millions of patients. The guanylin/GCC/cGMP/CFTR axis has proven far richer than initially anticipated — encompassing fluid secretion, visceral pain, intestinal stem cell regulation, and possible crosstalk with obesity and renal physiology.

The mechanistic insight that the same cGMP pathway that drives intestinal secretion also suppresses visceral nociception opened an entirely new conceptual framework for treating the hallmark symptoms of IBS-C (constipation + abdominal pain) through a single molecular target. This dual-action mechanism makes the guanylin/GCC system one of the most clinically successful translational stories in peptide biology.

Key Research Citations

3. De Sauvage FJ, et al. (1991). Primary structure and functional expression of the putative receptor for Escherichia coli heat-stable enterotoxin. Journal of Biological Chemistry, 266(27), 17912-17918. PMID: 1655753

4. Waldman SA, et al. (2003). Guanylyl cyclase C, a privileged tumor target in colorectal cancer. Drug News and Perspectives, 16(2), 79-87.

5. Rao SS, et al. (2012). Linaclotide significantly improves IBS-C symptoms. American Journal of Gastroenterology, 107(11), 1702-1712. [IBS-C Phase III data]

6. Lembo AJ, et al. (2011). Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology, 141(2), 432-442. PMID: 21645498

7. Busby RW, et al. (2010). Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. European Journal of Pharmacology, 649(1-3), 328-335. PMID: 20858478

8. Reigstad CS, et al. (2015). Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB Journal, 29(4), 1395-1403. [Context: enterochromaffin cells also produce guanylin]

---

This article is intended for Research Use Only (RUO). Guanylin/uroguanylin research tools and GCC-targeting compounds described herein, outside of their specific approved clinical uses, are for research applications only. All studies involving GCC/cGMP/CFTR pathway modulation must comply with applicable institutional and regulatory guidelines. This content does not constitute medical advice.